Cardiovascular

Does Acute Exenatide-Glucagon Co-Infusion Raise Myocardial Glucose Uptake in Type 2 Diabetes?

An acute crossover infusion study (n=8) found exenatide-glucagon co-infusion raised myocardial glucose uptake and a diastolic strain rate marker in type 2 diabetes. PICO summary and expert commentary.

Does Semaglutide Improve Symptoms and Weight Loss in Both Men and Women With Obesity-Related HFpEF?

Does 12-Month Home Telemonitoring Improve Outcomes in Older Adults with Hypertension and Diabetes?

A multicentre open-label RCT testing whether 12-month mHealth home telemonitoring improves blood pressure and HbA1c versus standard care in older adults with hypertension and type 2 diabetes. PICO summary and expert commentary.

Do Acarbose and Vildagliptin Affect TMAO Levels in Type 2 Diabetes?

An open-label randomized trial in newly diagnosed type 2 diabetes found acarbose and vildagliptin both lowered plasma TMAO, with a greater fall on acarbose. PICO summary and expert commentary.

Health Coaching and eGFR in Early Diabetic Kidney Disease: A Small RCT

A 92-patient randomized trial in Taiwan tested whether 6-month health coaching improves eGFR in type 2 diabetes with early-stage CKD. PICO summary and expert commentary.

Plasma Proteome Signatures of ASK1 Inhibition by Selonsertib in Diabetic Kidney Disease

An exploratory plasma proteomic analysis of the Phase 2b MOSAIC trial maps selonsertib activity to fibrosis, inflammation and oxidative-stress pathways in diabetic kidney disease, with PICO summary and expert commentary.

Finerenone in Chinese Patients with Type 2 Diabetes and CKD: A FIGARO-DKD Subgroup Analysis

A prespecified FIGARO-DKD subgroup analysis of 325 Chinese adults with type 2 diabetes and CKD found a significant reduction in the secondary kidney outcome with finerenone but no significant cardiovascular benefit. PICO summary and expert commentary.

Empagliflozin and Cardiac Reserve in Diabetic HFpEF: A Small Open-Label Mechanistic RCT

A single-centre, open-label randomised trial of empagliflozin 10 mg in 70 patients with type 2 diabetes and HFpEF found improved 6-minute walk distance and diastolic reserve markers. PICO summary and expert commentary.

Which is better for heart disease and diabetes: rosuvastatin with ezetimibe or higher-dose rosuvastatin?

A 223-patient randomised trial found single-pill rosuvastatin 10 mg plus ezetimibe was non-inferior, not superior, to rosuvastatin 20 mg for LDL-C lowering in ASCVD and type 2 diabetes. PICO summary and expert commentary.

DAPA ACT HF-TIMI 68: Rationale and Design of In-Hospital Dapagliflozin in Acute Heart Failure

Design paper for the DAPA ACT HF-TIMI 68 trial testing in-hospital dapagliflozin versus placebo in 2,401 patients with acute heart failure; no efficacy results are reported. PICO summary and expert commentary.